编者按：2026年欧洲肿瘤内科学会（ESMO）年会于10月23日至27日在西班牙马德里盛大举办。作为全球肿瘤领域极具影响力的顶级学术盛会，年会汇聚了全球顶尖肿瘤临床专家、科研学者及医药行业从业者，集中展示肿瘤领域前沿基础研究与临床转化成果，引领全球肿瘤诊疗技术发展方向。
本次大会妇科肿瘤赛道硕果颇丰，多位中国专家携重磅研究成果亮相，涵盖宫颈癌、卵巢癌、子宫内膜癌等常见妇科恶性肿瘤的靶向治疗、免疫治疗、联合放化疗、真实世界研究及多组学机制探索等多个热门方向，充分展现了中国妇科肿瘤领域的科研实力与临床创新水平。本文系统整理本次ESMO年会收录的中国专家口头报告、壁报研究成果，以期为行业学术交流与临床研究参考提供翔实资料。
快速口头报告
摘要号：1240RO
英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase 3 trial
中文标题：艾帕洛利托沃瑞利单抗（QL1706）联合化疗±贝伐珠单抗一线治疗持续性、复发性或转移性宫颈癌：一项双盲、随机、安慰剂对照Ⅲ期临床试验结果
讲者：刘继红教授 中山大学肿瘤防治中心
摘要号：1243RO
英文标题：JSKN033, a first-in-class subcutaneous (SC)-injected fixed-dose combination (FDC) of biparatopic anti-HER2 ADC and PD-L1 inhibitor, in pre-treated cervical cancer
中文标题：全球首创皮下注射双表位抗HER2 ADC联合PD-L1抑制剂固定复方制剂JSKN033用于经治宫颈癌的临床研究
讲者：吴小华教授 复旦大学附属肿瘤医院妇瘤科
摘要号：1244RO
英文标题：SHR-A2102, a novel nectin-4-targeted antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: results from a phase 2 study
中文标题：新型Nectin-4靶向抗体药物偶联物SHR-A2102治疗复发/转移性宫颈癌Ⅱ期临床研究结果
讲者：刘继红教授 中山大学肿瘤防治中心
壁报+电子壁报
摘要号：1348eP
英文标题：Association of location of BRCA1/BRCA2 mutations and benefit from PARP inhibitor maintenance in ovarian cancer: a systemic review
中文标题：卵巢癌BRCA1/BRCA2突变位点与PARP抑制剂维持治疗获益相关性的系统综述
讲者：Ming Wang (Beijing, China)
摘要号：1359eP
英文标题：Role of BTLA in Ovarian Cancer and Its Clinical Prognostic Significance Based on Multi-Omics Analysis.
中文标题：基于多组学分析BTLA在卵巢癌中的作用及其临床预后价值
讲者：Yiliminuer Abulajiang (Beijing, China)
摘要号：1362eP
英文标题：Multi-omics provide insights into the effect of neoadjuvant chemotherapy on the tumor microenvironment in cervical cancer
中文标题：多组学解析新辅助化疗对宫颈癌肿瘤微环境的调控作用
讲者：Silu Meng (Wuhan, China)
摘要号：1365eP
英文标题：Updated Efficacy and Safety Data of First-Line Anlotinib + Carboplatin/Paclitaxel Induction Followed by Anlotinib Maintenance in Advanced Ovarian Cancer: Phase II Multicenter Trial (ALTER-GO-010)
中文标题：安罗替尼联合卡铂/紫杉醇诱导后安罗替尼维持一线治疗晚期卵巢癌多中心Ⅱ期研究（ALTER-GO-010）更新疗效与安全性数据
讲者：Wenjun Cheng (Nanjing, China)
摘要号：1367eP
英文标题：CD8+/FOXP3+ Tumor-Infiltrating Lymphocytes and Systemic Immune-Inflammation Index revealed as a Predictor to Neoadjuvant Cadonilimab Plus Chemotherapy in Advanced Ovarian Cancer from the Phase II CANECT Trial
中文标题：Ⅱ期CANECT研究证实CD8+/FOXP3+肿瘤浸润淋巴细胞与全身免疫炎症指数可预测卡度尼利单抗联合化疗新辅助治疗晚期卵巢癌疗效
讲者：Jie Tang (Changsha, China)
摘要号：1368eP
英文标题：Clinical Practice Patterns of HER2 Testing and Treatment in Endometrial Cancer in China: A Cross-Sectional Survey
中文标题：中国子宫内膜癌HER2检测与治疗临床实践现状横断面调查
讲者：Jihong Liu (Guangzhou, China)
摘要号：1371eP
英文标题：Hyperthermic Intraperitoneal Treatment to Enhance the Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Ovarian Cancer: Stage 1 Results of a Phase II Trial (HIPET-IO) (NCT07068178)
中文标题：腹腔温热治疗提升晚期卵巢癌免疫检查点抑制剂疗效：Ⅱ期HIPET-IO研究（NCT07068178）I阶段结果
讲者：Hui Li (Guangzhou, China)
摘要号：1379eP
英文标题：Safety, Immunogenicity, and Efficacy of RG002, an mRNA-LNP-Based Therapeutic Targeting HPV 16/18 E2/E6/E7, in Patients with CIN2/3: Results from a Phase I and Expanded Clinical Study
中文标题：靶向HPV16/18 E2/E6/E7的 mRNA-LNP 治疗疫苗RG002用于CIN2/3患者的安全性、免疫原性及疗效I期及扩展临床研究结果
讲者：Shan Cen (Beijing, China)
摘要号：1382eP
英文标题：Study on the Comparison between Fangzhi Decoction and Kangfuxin in Preventing Gastrointestinal Toxicity Induced by Concurrent Chemoradiotherapy for Cervical Cancer
中文标题：防芷汤与康复新液预防宫颈癌同步放化疗所致胃肠道毒性对比研究
讲者：Shengfa Su (Guiyang, China)
摘要号：1386eP
英文标题：Exploratory study of TP53 mutations in circulating tumor DNA as prognostic and longitudinal monitoring biomarkers for relapsed ovarian carcinoma patients
中文标题：循环肿瘤DNA TP53突变作为复发性卵巢癌预后及动态监测生物标志物探索研究
讲者：Zheng Feng (Shanghai, China)
摘要号：1388eP
英文标题：Rapid Histopathological Regression of CIN2 with APL-1702 Photodynamic Therapy: Preliminary Findings from a Multicenter Study
中文标题：APL-1702光动力治疗实现CIN2快速组织病理学缓解：一项多中心研究初步结果
讲者：Yu Zhang (Changsha, China)
摘要号：1394eP
英文标题：Intimate Partner Violence-Related Stress Accelerates Cervical Cancer Development via a Brain–Cholinergic Nerve–Tumor Axis
中文标题：亲密伴侣暴力相关应激通过脑-胆碱能神经-肿瘤轴促进宫颈癌进展
讲者：Jingrui Jiang (Wuhan, China)
摘要号：1395eP
英文标题：Association of Silva Pattern C with Lymph Node Metastasis Count and Prognosis in Cervical Adenocarcinoma After Radical Hysterectomy : Construction of a Nomogram Prediction Model.
中文标题：宫颈腺癌根治术后Silva C型与淋巴结转移数目及预后相关性：列线图预测模型构建
讲者：Jiehui Li (Guiyang, China)
摘要号：1396eP
英文标题：Clinical landscape of oncolytic virotherapy in gynecologic malignancies
中文标题：溶瘤病毒疗法在妇科恶性肿瘤中的临床应用全景
讲者：Kaiyu Fu (Chengdu, China)
摘要号：1403eP
英文标题：RBP4 orchestrates metabolic reprogramming of ovarian cancer and the omentum microenvironment for cancer dissemination
中文标题：RBP4调控卵巢癌及大网膜微环境代谢重编程促进肿瘤播散
讲者：Weiao Qu (Tianjin, China)
摘要号：1405eP
英文标题：Single-cell RNA sequencing reveals the important role of intercommunication between epithelial cells and cancer-associated fibroblasts in the peritoneal metastasis of high-grade serous ovarian cancer
中文标题：单细胞RNA测序揭示上皮细胞与癌相关成纤维细胞互作在高级别浆液性卵巢癌腹膜转移中的关键作用
讲者：Xiaoting Zhao (Beijing, China)
摘要号：1406eP
英文标题：Therapy-selected primitive hematopoietic clones in PARP inhibitor–associated t-MN: longitudinal single-cell insights from ovarian cancer
中文标题：PARP抑制剂相关治疗相关髓系肿瘤中经药物筛选的原始造血克隆：卵巢癌患者纵向单细胞研究
讲者：Yuanqiong Duan (Chengdu, China)
摘要号：1407eP
英文标题：HPV18 is a poor prognostic factor in patients with small cell neuroendocrine cervical cancer.
中文标题：HPV18是宫颈小细胞神经内分泌癌不良预后因素
讲者：Chyong-Huey Lai (Taoyuan City, Taiwan)
摘要号：1412eP
英文标题：Anxiety-driven sympathetic nerve–CAF–NGF axis promotes ovarian cancer progression and immune evasion
中文标题：焦虑介导交感神经-癌相关成纤维细胞-NGF轴促进卵巢癌进展与免疫逃逸
讲者：Yueming Zhang (Suzhou, China)
摘要号：1416eP
英文标题：Clinical Characteristics Analysis of a Single-Cell and Spatial Transcriptomics Cohort Treated with Zimberelimab Combined with Chemoradiotherapy for Intermediate- and Advanced-Stage Cervical Cancer
中文标题：基于单细胞及空间转录组队列分析Zimberelimab联合放化疗治疗中晚期宫颈癌的临床特征
讲者：Yunyan Zhang (Harbin, China)
摘要号：1420eP
英文标题：Epidemiology and Treatment Options for Cervical Cancer Patients Aged ≤25 Years based on SEER database and Real world research
中文标题：基于SEER数据库与真实世界研究的25岁及以下宫颈癌患者流行病学特征及治疗方案分析
讲者：Chen Ji (Beijing, China)
摘要号：1425eP
英文标题：Real-world outcomes of FRα targeting treatment with MIRV in Chinese PROC patients
中文标题：MIRV靶向叶酸受体α治疗中国铂耐药卵巢癌患者真实世界疗效
讲者：Jing Li (Shanghai, China)
摘要号：1426eP
英文标题：Correlation Between Recurrence Patterns and Clinical Risk Factors Following Prophylactic Irradiation of the the Inguinal Lymphatic Drainage Area in Stage IIIA Cervical Cancer
中文标题：IIIA期宫颈癌腹股沟淋巴引流区预防性放疗后复发模式与临床危险因素相关性
讲者：Fenghu Li (Guiyang, China)
摘要号：1427eP
英文标题：Clinical Characteristics and Treatment Strategy Analysis of 21 Cervical Cancer Patients Undergoing Hysterectomy After Radical Radiotherapy
中文标题：21例根治性放疗后接受子宫切除术宫颈癌患者临床特征与治疗策略分析
讲者：Zhuoying Du (Beijing, China)
摘要号：1428eP
英文标题：Neoadjuvant Iparomlimab and Tuvonralimab (PD-1/CTLA-4 Bifunctional Antibody) Plus Chemotherapy Enables Radical Surgery in Locally Advanced Cervical Cancer
中文标题：PD-1/CTLA-4双特异性抗体艾帕洛利托沃瑞利单抗新辅助化疗可实现局部晚期宫颈癌根治性手术
讲者：Wei Sheng (Jinan, China)
摘要号：1430eP
英文标题：Reduced-Dose Dexamethasone (Dex) Plus Netupitant/Palonosetron (NEPA) for Prevention of Nausea and Vomiting in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy（CCRT）: An Interim Analysis
中文标题：减量地塞米松联合奈妥匹坦/帕洛诺司琼预防宫颈癌同步放化疗恶心呕吐中期分析
讲者：Re Yang (Guiyang, China)
摘要号：1440eP
英文标题：MEOX2 promotes the survival and dissemination of ovarian cancer cells via the activation of UPR under nutrient stress
中文标题：营养应激下MEOX2通过激活未折叠蛋白反应促进卵巢癌细胞存活与播散
讲者：Rui Zhou (Tianjin, China)
摘要号：1441eTiP
英文标题：Prospective Single-Arm Exploratory Study of Disitamab Vedotin Combination Regimen as Neoadjuvant Therapy for HER2-Expressing Ovarian Cancer
中文标题：维迪西妥单抗联合方案用于HER2表达卵巢癌新辅助治疗前瞻性单臂探索研究
讲者：Jing X. Tong (Shenyang, China)
摘要号：1253P
英文标题：Biparatopic Anti-HER2 Antibody Drug Conjugate (ADC) JSKN003 in Platinum-Resistant Ovarian Cancer (PROC): updated Overall Survival (OS) Analysis from Two Early-Phase Studies After Median Follow-Up (mFU) of 20.5 Months
中文标题：双表位抗HER2 ADC药物JSKN003治疗铂耐药卵巢癌：两项早期研究中位随访20.5个月更新总生存数据
讲者：Xiaohua Wu (Shanghai, China)
摘要号：1254P
英文标题：Disitamab Vedotin (RC48)-based Therapy in Heavily Prior Treated Patients with Recurrent Ovarian Cancer: A Real-World Multicenter Study
中文标题：基于维迪西妥单抗（RC48）方案治疗多线经治复发性卵巢癌多中心真实世界研究
讲者：Lei Yuan (Shanghai, China)
摘要号：1255P
英文标题：Elfetabart drozuntecan (Elfe-D; DB-1311/BNT324 [B7H3 ADC]) in patients with platinum-resistant ovarian cancer (PROC): Efficacy and safety data from a Phase 2 dose optimization cohort
中文标题：B7H3 ADC药物 Elfetabart drozuntecan（DB-1311/BNT324）治疗铂耐药卵巢癌Ⅱ期剂量优化队列疗效与安全性数据
讲者：Jianqing Zhu (Hangzhou, China)
摘要号：1259P
英文标题：Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) in Post-Platinum Advanced Mismatch Repair Proficient (pMMR) Endometrial Cancer (EC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
中文标题：芦康沙妥珠单抗联合帕博利珠单抗治疗铂耐药晚期错配修复完整子宫内膜癌Ⅱ期研究结果（2870-002/SKB264-II-06）
讲者：Xiaohua Wu (Shanghai, China)
摘要号：1260P
英文标题：Updated Progression-Free Survival (PFS) Results from the FLAMES Study: First-Line Maintenance Senaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (aOC)
中文标题：FLAMES研究更新无进展生存数据：塞那帕利一线维持治疗初诊晚期卵巢癌
讲者：Xiaohua Wu (Shanghai, China)
摘要号：1265P
英文标题：3-year survival outcomes of image-guided radiotherapy combined with nimotuzumab for elderly patients with locally advanced cervical squamous cell carcinoma: a multi-center phase 2 trial
中文标题：图像引导放疗联合尼妥珠单抗治疗老年局部晚期宫颈鳞癌3年生存结局多中心Ⅱ期研究
讲者：Ang Qu (Beijing, China)
摘要号：1271P
英文标题：Efficacy and Safety of MSLN-Specific Autologous CAR-T Cell Therapy in Patients with Recurrent Ovarian Cancer: An Investigator-Initiated Single-Arm Clinical Trial
中文标题：间皮素靶向自体CAR-T细胞治疗复发性卵巢癌疗效与安全性：一项研究者发起单臂临床试验
讲者：Guohui Qin (Zhengzhou, China)
摘要号：1276P
英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and definitive radiotherapy as first-line treatment for oligometastatic cervical cancer: a single-arm, phase II study
中文标题：艾帕洛利托沃瑞利单抗（QL1706）化疗同步根治性放疗一线治疗寡转移宫颈癌单臂Ⅱ期研究
讲者：Jing Liu (Jinan, China)
摘要号：1277P
英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab induced concurrent chemoradiotherapy for high-risk locally advanced cervical cancer: A Prospective, Single-Arm Phase II Clinical Trial
中文标题：艾帕洛利托沃瑞利单抗（QL1706）±贝伐珠单抗化疗诱导同步放化疗治疗高危局部晚期宫颈癌前瞻性单臂Ⅱ期临床研究
讲者：Xiao'juan Lv (Hangzhou, China)
摘要号：1280P
英文标题：Long Term Follow-up Results from a Phase I/II Study of Nilvanstomig (ZG005), a Bispecific Antibody Targeting PD-1 and TIGIT, as Monotherapy in Patients with Advanced Cervical Cancer
中文标题：PD-1/TIGIT双特异性抗体 Nilvanstomig（ZG005）单药治疗晚期宫颈癌I/Ⅱ期长期随访结果
讲者：Shuxia Cheng (Zhengzhou, China)
摘要号：1282P
英文标题：Phase I/II Study of Nilvanstomig (ZG005) Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment for Advanced Cervical Cancer: Updated Results of Efficacy and Safety
中文标题：PD-1/TIGIT双特异性抗体 Nilvanstomig（ZG005）联合化疗±贝伐珠单抗一线治疗晚期宫颈癌 I/Ⅱ期更新疗效与安全性数据
讲者：Hanmei Lou (Hangzhou, China)
摘要号：1283P
英文标题：Phase II Study of Fruquintinib Plus Utidelone in Platinum-Resistant Recurrent Ovarian Cancer (FRUTD Trial)
中文标题：呋喹替尼联合优替德隆治疗铂耐药复发性卵巢癌Ⅱ期FRUTD临床研究
讲者：Zheng Feng (Shanghai, China)
摘要号：1289P
英文标题：Subtype-Specific Outcomes and Risk-Adapted Treatment Patterns in Endometrial Stromal Sarcoma: A 214-Patient Retrospective Cohort
中文标题：子宫内膜间质肉瘤各亚型生存结局及风险分层治疗模式：214例患者回顾性队列研究
讲者：Lingcong Yang (Fuzhou, China)
摘要号：1297P
英文标题：Preliminary outcomes of a phase II study of the highly potent PI3K/mTOR dual inhibitor WX390 monotherapy in patients with platinum-resistant ovarian clear cell carcinoma harboring PIK3CA mutations
中文标题：高选择性PI3K/mTOR双靶点抑制剂WX390单药治疗伴PIK3CA突变铂耐药卵巢透明细胞癌Ⅱ期初步结果
讲者：Jiajia Li (Shanghai, China)
摘要号：1301P
英文标题：A real-world study of patients with gastric-type adenocarcinoma of the cervix
中文标题：宫颈胃型腺癌患者真实世界临床研究
讲者：Mengting Che (Chengdu, China)
摘要号：1303P
英文标题：Efficacy of Iparomlimab and Tuvonralimab (QL1706) in Cervical Cancer: A Multicenter, Prospective, Real-World Study
中文标题：艾帕洛利托沃瑞利单抗（QL1706）治疗宫颈癌多中心前瞻性真实世界疗效研究
讲者：Yan Lu (Nantong, China)
摘要号：1315P
英文标题：Redefining risk in cervical cancer: a novel histology-site subtype framework uncovers high- Risk adenocarcinoma through risk reversal
中文标题：宫颈癌风险分层再定义：全新组织 - 解剖分型体系通过风险反转识别高危腺癌亚型
讲者：Xiaolian Peng (Dongguan, China)
摘要号：1326P
英文标题：Induction Weekly Chemoimmunotherapy with Enlonstobart as a Priming Approach to De-escalated Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
中文标题：恩朗苏拜单抗周疗化疗免疫诱导方案用于局部晚期宫颈癌降阶梯同步放化疗预处理
讲者：Ai Huang (Wuhan, China)
摘要号：1327P
英文标题：Longitudinal Changes of Systemic Tumoe Immune Envoriment (STIE) in Cervical Cancer Patients Receiving Radiotherapy
中文标题：接受放疗的宫颈癌患者全身肿瘤免疫微环境纵向动态变化规律
讲者：Caining Zhao (Shenzhen, China)